CorMedix Inc. (CRMD) announced Friday the pricing of its public offering of 6,604,507 shares of common stock, expected to generate gross proceeds of approximately $85 million.
The offering includes a 30-day option granted to underwriters to purchase up to an additional 15 percent of the shares offered.
The offering is expected to close on or about June 30, 2025, subject to customary closing conditions.
CorMedix plans to use the net proceeds for general corporate purposes, including working capital, R&D expenses, and potential strategic transactions such as acquisitions or partnerships.
CorMedix is focused on commercializing DefenCath, its FDA-approved catheter lock solution, and expanding into additional indications including pediatric and TPN patient populations.
Currently, CRMD is trading at $12.45, down by 16.95 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.